Navigation Links
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
Date:12/3/2008

400 mg once daily). If the strong inhibitor is discontinued, a washout period should be allowed before Tasigna is adjusted upward to the indicated dose. Close monitoring for prolongation of the QT interval is indicated for patients who cannot avoid strong CYP3A4 inhibitors. Grapefruit products and other foods that are known to inhibit CYP3A4 should also be avoided.

Concomitant strong CYP3A4 inducers

The concomitant use of strong CYP3A4 inducers should be avoided (including, but not limited to, dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital). Patients should also refrain from taking St John's Wort. If patients must be co-administered a strong CYP3A4 inducer, the dose of Tasigna may need to be increased, depending on patient tolerability. If the strong inducer is discontinued, the Tasigna dose should be reduced to the indicated dose. Tasigna is a competitive inhibitor of CYP3A4, CYP2C8, CYP2C9, CYP2D6 and UGT1A1. Since warfarin is metabolized by CYP2C9 and CYP3A4, it should be avoided if possible. Tasigna inhibits human P-glycoprotein. If Tasigna is administered with drugs that are substrates of Pgp, increased concentrations of the substrate are likely and caution should be exercised. Tasigna may also induce CYP2B6, CYP2C8 and CYP2C9. Therefore, Tasigna may alter serum concentration of other drugs.

Food effects

Food increases blood levels of Tasigna. Patients should avoid food 2 hours before and 1 hour after taking dose.

Lactose

Since the capsules contain lactose, Tasigna is not recommended for patients with rare hereditary problems of galactose intolerance, severe lactase deficiency, or of glucose-galactose malabsorption.

Pregnancy

Fetal harm can occur when Tasigna is administered to a pregnant woman. Women should be advised not to become pregnant when taking Tasigna.'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
4. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
5. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
6. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. New Conflict of Interest Violations Revealed at California Stem Cell Institute
9. St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia
10. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
11. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Frost & Sullivan,s ... to speaking at the 2010 International Consumer ... January 9, 2010 in Las Vegas. ... of consumer-based digital health and wellness devices, ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, Bujnoch focuses on patient ...
(Date:12/16/2009)... Dec. 16 The Boards of Silence ... delighted to announce the merger of their businesses ... of RNAi (RNA interference). The enlarged company, ... RNAi discovery, development and delivery technologies, a broad ... portfolio of intellectual property. ,, The Directors ...
(Date:12/16/2009)... Dec. 16 Keryx Biopharmaceuticals, Inc. ... initiation of a Phase 3 registration clinical ... pathway inhibitor, in relapsed / refractory multiple ... Phase 3 Randomized Study to Assess the ... the Combination of Bortezomib (Velcade®) and Dexamethasone ...
Breaking Medicine Technology:Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit 2Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 2Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 5Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 2Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 3Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 4Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 5Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 7Abbott Cuts Use of Oil and Coal by 35 Percent 5108 1Abbott Cuts Use of Oil and Coal by 35 Percent 5108 2Abbott Cuts Use of Oil and Coal by 35 Percent 5108 3Urologists Radiologists Patients Benefit From New Clinical Prostate Visualization System 5105 1Urologists Radiologists Patients Benefit From New Clinical Prostate Visualization System 5105 2 2416 8 million grant awarded to develop platelet recovery treatments 58550 1 2416 8 million grant awarded to develop platelet recovery treatments 58550 2
(Date:12/16/2009)... owner of Supreme Ultimate Fitness in Boca Raton, ... his students in the new year. The difference with this ... own prize or against each other. They will be losing ... Society in Boca Raton, FL. ,, "For every ... February 28, 2010 I will donate $10 to the Tri ...
(Date:12/16/2009)... , , TUESDAY, Dec. 15 (HealthDay News) -- If that ... on your life that you just can,t wait to have ... you might want to wait at least six months before ... be even better. , The study found that when ... chances of the baby dying, being born prematurely, having birth ...
(Date:12/16/2009)... received a further 1.6 million Euro in capital funding to ... in order to meet the rapidly growing demand for this promising ... A/S that continue to own each about 50% of the company. ... ... Unisense FertiliTech A/S has received a further 1.6 million Euro ...
(Date:12/16/2009)... announce being presented with the Weatherhead 100 Upstart Award on December ... in Northeast Ohio and is a testament to hard work, commitment, ... ... (PRWEB) December 16, 2009 -- Request A Test, Ltd. ... Award on December 3, 2009. The Weatherhead 100 showcases the ...
(Date:12/16/2009)... will continue to offer free nationwide confidential legal consultations for ... effects such as: Birth Defects, Attempted Suicide, Suicide and Addiction ... free at 1-800-856-6405 or go to the firm’s website at ... form. , ... (PRWEB) December 16, ...
Breaking Medicine News(10 mins):Health News:Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter 2Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3Health News:Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 2Health News:Request A Test Receives Weatherhead 100 Upstart Award 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 3
... May 29 Britannia members overwhelmingly endorse plans ... to create new super-mutual:- New business will be ... services, providing ethical alternative to banks- Strong strategic ... expected efficiency and revenue benefits of pounds Sterling ...
... WASHINGTON, May 29 The following advisory is being ... http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ) WHAT: American ... June 4, 10 a.m. WHERE : National Press Club ... American Life League, Pharmacists for Life International, Pro-Life ...
... Beckman Coulter, Inc. (NYSE: BEC ), ... that simplify, automate, and innovate complex biomedical testing, ... president of strategy, will present at the Goldman ... at 11:00 a.m. (ET).(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO )The ...
... Fla.--The vast majority of advanced colon cancer patients in ... of prescription drugs for managing chemotherapy side effects, such ... to reduce drug cost burdens after joining the clinical ... Dana-Farber Cancer Institute in Boston. Although few patients reported ...
... New mushrooms offer 100 percent of recommended daily Vitamin ... Through a truly collaborative research effort with the United ... been successful in replicating what happens in nature when ... light the same way humans do, by converting the ...
... and Long-Term Care to Youth with Special NeedsWASHINGTON, May 29 ... anniversary with the launch of Home at HSC , ... home environment for long-term patients age 6 months to 21 ... provide in a home, group home or typical long-term care ...
Other Medicine News:Health News:Britannia Members Back Super-Mutual Merger With the Co-Operative Financial Services 2Health News:Britannia Members Back Super-Mutual Merger With the Co-Operative Financial Services 3Health News:Britannia Members Back Super-Mutual Merger With the Co-Operative Financial Services 4Health News:The Pill Kills Women: Largest Protest Against Birth Control Pill 2Health News:1 in 10 advanced colon cancer patients worry about prescription drug costs 2Health News:Monterey Mushrooms Launches Vitamin D Enriched Sun Grill-A-Bella and White Mushrooms 2Health News:Home At HSC 2
... FLEXILOG antimony pH catheters are designed for patient ... ,All catheters are number marked at 5cm intervals ... than sixteen individual models are available spanning most ... or multi-use models with one or two sensors., ...
... catheter has two sensors and a black ... allowing optimal placement in relation to the ... esophageal pH monitoring. , ,Alpine's VersaFlex ... on the market (4.7 French), and are ...
... Slimline single-use pH catheters are efficient, ... and allow greater patient comfort during ... pH measurement systems have been designed ... allow an accurate room-temperature calibration. The ...
FLEXILOG accessory....
Medicine Products: